Download Files:
Fezagepras (sodium)
$180 – $1,350
Products Details
Product Description
– Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras sodium decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].
Web ID
– HY-100775
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C13H17NaO2
References
– [1]Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365.|[2]Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367(1):71-81.
CAS Number
– 1254472-97-3
Molecular Weight
– 228.26
Compound Purity
– 99.65
SMILES
– O=C(O[Na])CC1=CC(CCCCC)=CC=C1
Clinical Information
– Phase 3
Research Area
– Metabolic Disease; Inflammation/Immunology
Solubility
– DMSO : ≥ 64 mg/mL|H2O : ≥ 100 mg/mL
Target
– Free Fatty Acid Receptor;GPR84
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
